Papers
Monoclonal antibodies in cancer therapy
Monoclonal antibody-based treatment of cancer has been established as one of the most successful therapeutic strategies for both hematologic malignancies and solid tumors in the last 20 years. The initial combining of serological techniques for cancer cell surface antigen discovery with hybridoma technology led to a series of landmark clinical trials that paved the way for new generation antibodies and subsequent clinical success. Optimization of anti-tumor immune responses through Fc modifications has also made a major contribution to clinical efficacy. The modulation of immune system interplay with tumor cells through targeting of T cell receptors has emerged as a powerful...
Read more…Translating basic mechanisms of IgG effector activity into next generation cancer therapies
Monoclonal antibodies of the immunoglobulin G (IgG) isotype have become a well-established therapeutic tool for the targeting of malignant cells in tumor patients. Despite tremendous success in the treatment of lymphoma and breast cancer, it has also become clear that we may not be able to further improve antibody therapy of cancer by simply generating more tumor-specific antibodies with a higher affinity. Instead, the work of many groups in the past years suggests that optimizing the recruitment of effector functions provided by the adaptive and innate immune systems via engineering of the IgG constant domain may hold great promise to...
Read more…Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on
The era of modern antibody therapy begins with Rodney Porter’s Nobel Prize-winning report on the basic structure of the immunoglobulin molecule. Using papain for digestion of a 7s rabbit antibody preparation, he obtained two almost identical antigen-binding fragments (Fab) that blocked antigen precipitation by the parent antibody while a third, easily crystallizable fragment (Fc) was found inactive (1). From a historian’s viewpoint, it is striking that, almost simultaneously with these first insights into the antibody’s structure and function, the idea of an artificially constructed bispecific antibody was born. Without a clear image of the now heraldic Y and its underlying...
Read more…News
May 13, 2012
Some melanomas use cloaking protein to hide from cancer-killing immune cells
Scientists at Johns Hopkins and Yale have found that melanoma cells use a cloaking protein to hide from immune cells poised to attack the cancer. Nearly 40 percent of their sampling of melanoma tissues contained the B7-H1 protein, also called PD-L1, and s...
Read more…May 9, 2012
NY’s Cancer Research Institute looks to boost cancer immunotherapy
When the Cancer Research Institute was founded in 1953 in New York, it set out to pursue an idea that was radical at the time—the notion that mobilizing the body’s innate immune mechanisms could be the key to fighting cancer. Since then, the organization ...
Read more…May 8, 2012
Generex announces presentations of antigen express AE37 breast cancer vaccine data at ASCO 2012
Generex Biotechnology Corporation announced today that abstracts featuring the AE37 breast cancer vaccine clinical program of Generex wholly-owned subsidiary Antigen Express, Inc. will be presented at the Annual Meeting of the American Society of Clinical...
Read more…Conferences
NYAS Cancer Vaccines and Cancer Immunotherapy and Immunomodulation
Cancer vaccines have been developed largely as therapeutic approaches targeting specific tumor antigens while sparing the deleterious and generalized immune-suppressive effects of radiation and chemotherapy. This symposium will highlight current approache...
Read more…Keystone Symposia: The Role of Inflammation during Carcinogenesis
The conference will address the mechanisms behind the recruitment of the immune cells and their function, the switches in type of inflammatory responses during tumor progression and the actions of these cells in tumor promotion both at the primary and met...
Read more…10th Annual Meeting of the Association for Cancer Immunotherapy (CIMT): Towards the Next-Generation Immunotherapy
CIMT 2012 will provide a stage for reflecting the aggregate knowledge of 10 years of cancer immunotherapy, presenting current scientific approaches and discussing next-generation therapies. Highlights of the 10th anniversary meeting will be individuali...
Read more…Resources
LICR Tetramers
Soluble tetrameric MHC/peptide complexes to identify and monitor tumor antigen-specific T cells...
Read more…SEREX Review
Identification of human tumor antigens by serological expression cloning – an online review on SEREX...
Read more…ISSN 1424-9634 | Copyright © 2001—2012 by the Cancer Research Institute
